About
A biopharmaceutical company
Adcytherix is focused on designing and developing novel antibody-drug conjugates (ADCs) that go beyond current limitations.
By combining cutting-edge payload innovation with deep ADC development expertise, the company aims to transform targeted therapies for cancer and other diseases of high unmet medical need.
Driving the development of transformational ADC technology
Most ADCs rely on two classes of payloads, tubulin and topoisomerase 1 inhibitors.
Adcytherix is exploring novel payloads classes with mechanisms of action selected to address tumor resistance while improving safety, with the potential to treat a wider range of cancers.
Team
Adcytherix was founded by Jack Elands and Pontifax Venture Capital.
Adcytherix is led by a seasoned management team and is supported by a network of world-leading experts in the field of ADC development.
Management team
Jack Elands
Founder, Chief Executive Officer
Dr. Jack Elands is founder and former CEO of Emergence Therapeutics, Talix Therapeutics, CEO of BliNK Biomedical and CEO and co-founder of Amakem, CEO of Vitec, co-founder of MImAbs
Xavier Preville
Co-founder, VP and head of research & preclinical development
Dr. Xavier Preville is co-founder and former CSO of Emergence Therapeutics, CSO at Talix Therapeutics, director of preclinical development at Transgene and BT Pharma (Genticel)
Carsten Dehning
Co-founder, Chief Financial Officer
Carsten Dehning is co-founder and former CFO of Emergence Therapeutics, CFO, CEO and senior advisor of various companies and investors in the healthcare sector
Thierry Menguy
VP and head of CMC operations
Dr. Thierry Menguy is the former head of CMC at LinKinVax, CTO and co-founder at ElsaLys Biotech. He has also held senior positions in CMC and R&D of large molecules at Transgene
Inka Pawlitzky
VP and head of clinical development
Dr. Inka Pawlitzky is former senior medical director and program lead oncology at Faron Pharmaceuticals, director oncology development at Allucent and consultant at SMS Oncology
Julia Gavrilyuk
VP and head of ADC technology development
Dr. Julia Gavrilyuk is co-founder and former CEO of Yarrow Therapeutics, senior principal scientist at Abbvie, head of discovery chemistry at Stemcentrx
Holger Karsunky
VP and Head of ADC Discovery
Dr. Holger Karsunky is co-founder and former CSO of Yarrow Therapeutics, senior director oncology discovery at Abbvie Stemcentrx and director preclinical at Cellerant Therapeutics
Investors
Supervisory Committee
Jack Elands
President of Adcytherix
Iyona Rajkomar
Managing Partner at DawnBiopharma (a platform controlled by KKR)
Laurent Higueret
Deputy Director at Bpifrance’s Large Venture Fund
Ohad Hammer
Partner at Pontifax Venture Capital
Olivier Martinez
Senior Investment Director at Bpifrance’s InnoBio funds
Peter Neubeck
Partner at Kurma Partners
Sofia Ioannidou
Partner at Andera Partners
Ximing Ding
Principal at Pureos Bioventures
